A Phase I/II Trial of Pembrolizumab (MK-3475) and Poly-ICLC in Patients With Metastatic Mismatch Repair-proficient (MRP) Colon Cancer
Not yet recruiting
Phase of Trial: Phase I/II
Latest Information Update: 30 Nov 2017
At a glance
- Drugs Pembrolizumab (Primary) ; Poly ICLC (Primary)
- Indications Colon cancer
- Focus Adverse reactions; Therapeutic Use
- 25 Nov 2017 Planned End Date changed from 1 Dec 2019 to 1 Dec 2020.
- 25 Nov 2017 Planned primary completion date changed from 1 Dec 2018 to 1 Dec 2019.
- 19 Jul 2016 New trial record